Pedersen and Stine Jacobsen COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday ...

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual ...

The boss of the drugs giant behind Ozempic has quit after falling behind in the global race to develop weight-loss medication ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said Friday its CEO was ...

"Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk Foundation, the Novo Nordisk Board and Lars Fruergaard Jørgensen have jointly concluded that ...

U.S.-listed shares of Novo Nordisk declined in premarket trading Friday on the surprise news that CEO Lars Fruergaard ...

Ozempic was approved to treat Type 2 diabetes in 2017, and it’s become increasingly popular among those who don’t have the ...

Weight loss drugs Ozempic and Wegovy would no longer be covered by California’s health insurance for low-income people under ...

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.